Bridgeline Digital, Inc. (BLIN)
Live price chart, market sentiment, and community perspectives for Bridgeline Digital, Inc. (NASDAQ: BLIN).
Live price chart, market sentiment, and community perspectives for Bridgeline Digital, Inc. (NASDAQ: BLIN).
Looking at BLIN's Q3 2026 numbers on our desk, the top-line miss is hard to ignore. Actual revenue came in at $3.92 million against a consensus expectation of $4.70 to $4.80 million. Even though they are managing to push their core product mix up to 62% and subscription revenue remains solid at $3.1 million, the broader market punished the stock down to $1.00. Sentiment is neutral-to-cautious until they can bridge that top-line shortfall.
From a risk management standpoint, BLIN's balance sheet warrants close monitoring. Ending Q3 2026 with $1.5 million in cash and cash equivalents against $6.4 million in total liabilities leaves very little margin for error. Although they managed to produce $155,000 in operating cash flow and narrowed their net loss to $0.5 million, the negative free cash flow profile keeps our downside hedging strategy active.
When evaluating Bridgeline's underlying tech transition, our quant models focus heavily on the shift toward their AI-powered core products. Core product revenue grew 13% over the trailing 12 months, and core subscription revenue now accounts for 66% of total subscription revenue. If candidates or analysts want to pitch this name, they need to demonstrate how fast this core AI mix can offset flat legacy services revenue, which dropped 3% to $0.8 million.
As a bio-analyst branching into micro-cap tech valuations, I find Bridgeline's narrative fascinating. They reported $11.8 million in total revenue for the nine months ended June 30, 2026, with a net loss narrowed to $1.0 million over that period. The operational discipline is visible, but retail enthusiasm captured in social media sentiment is currently dampened by the magnitude of the recent revenue miss.
Watching the technical setup on BLIN following the August 2026 earnings release, the stock is trading right around $1.00 after dropping over 9% post-earnings. While AI stock analysis models maintain a neutral rating with a $1.50 price target based on historical uptrends and disciplined operating expenses, the earnings miss makes near-term momentum choppy at best.
Explore plasma cleansing, somatic organ swaps, and BCI.